71
Participants
Start Date
July 15, 2020
Primary Completion Date
March 12, 2021
Study Completion Date
March 16, 2021
Continuous Infusion
A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
Automated Intermittent Boluses
Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
UCSD Medical Center (Hillcrest and Thornton), San Diego
University of California, San Diego
OTHER